A mathematical model of the metastatic bottleneck predicts patient outcome and response to cancer treatment.


Journal

PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922

Informations de publication

Date de publication:
10 2020
Historique:
received: 27 01 2020
accepted: 15 06 2020
revised: 27 10 2020
pubmed: 3 10 2020
medline: 28 1 2021
entrez: 2 10 2020
Statut: epublish

Résumé

Metastases are the main reason for cancer-related deaths. Initiation of metastases, where newly seeded tumor cells expand into colonies, presents a tremendous bottleneck to metastasis formation. Despite its importance, a quantitative description of metastasis initiation and its clinical implications is lacking. Here, we set theoretical grounds for the metastatic bottleneck with a simple stochastic model. The model assumes that the proliferation-to-death rate ratio for the initiating metastatic cells increases when they are surrounded by more of their kind. For a total of 159,191 patients across 13 cancer types, we found that a single cell has an extremely low median probability of successful seeding of the order of 10-8. With increasing colony size, a sharp transition from very unlikely to very likely successful metastasis initiation occurs. The median metastatic bottleneck, defined as the critical colony size that marks this transition, was between 10 and 21 cells. We derived the probability of metastasis occurrence and patient outcome based on primary tumor size at diagnosis and tumor type. The model predicts that the efficacy of patient treatment depends on the primary tumor size but even more so on the severity of the metastatic bottleneck, which is estimated to largely vary between patients. We find that medical interventions aiming at tightening the bottleneck, such as immunotherapy, can be much more efficient than therapies that decrease overall tumor burden, such as chemotherapy.

Identifiants

pubmed: 33006977
doi: 10.1371/journal.pcbi.1008056
pii: PCOMPBIOL-D-20-00136
pmc: PMC7591057
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1008056

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Cell. 2014 Aug 28;158(5):1110-1122
pubmed: 25171411
Nat Rev Clin Oncol. 2014 Sep;11(9):509-24
pubmed: 25001465
Cancer Res. 2001 Jan 1;61(1):333-8
pubmed: 11196183
J Natl Cancer Inst. 1970 Oct;45(4):773-82
pubmed: 5513503
Cancer Res. 1976 Mar;36(3):889-94
pubmed: 1253177
Cancer Res. 2000 May 1;60(9):2541-6
pubmed: 10811137
PLoS Comput Biol. 2019 Nov 21;15(11):e1007423
pubmed: 31751332
Adv Cancer Res. 1990;54:159-211
pubmed: 1688681
Nat Rev Genet. 2007 May;8(5):341-52
pubmed: 17440531
Nature. 2016 Dec 22;540(7634):552-558
pubmed: 27974799
PLoS Biol. 2019 Aug 5;17(8):e3000399
pubmed: 31381560
J Theor Biol. 2006 Dec 7;243(3):407-17
pubmed: 16930629
Nat Rev Cancer. 2002 Aug;2(8):563-72
pubmed: 12154349
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Int J Cancer. 2011 Jun 1;128(11):2527-35
pubmed: 21365651
Cancer Res. 2016 Feb 1;76(3):535-47
pubmed: 26511632
Br J Cancer. 1984 Jun;49(6):709-15
pubmed: 6733019
Nat Rev Cancer. 2003 Jun;3(6):453-8
pubmed: 12778135
Cancer Res. 2002 Feb 1;62(3):887-91
pubmed: 11830548
Cancer Metastasis Rev. 1989 Aug;8(2):98-101
pubmed: 2673568
Cell. 2012 Jan 20;148(1-2):362-75
pubmed: 22265421
Phys Biol. 2014 Aug;11(4):046003
pubmed: 25033031
J Theor Biol. 2000 Mar 21;203(2):177-86
pubmed: 10704301
Cancer. 1975 Jan;35(1):98-110
pubmed: 162854
Biometrics. 1976 Sep;32(3):535-50
pubmed: 963169
Cancer Res. 2014 Nov 15;74(22):6397-407
pubmed: 25217520
Nat Rev Cancer. 2009 Apr;9(4):274-84
pubmed: 19308067
Eur J Cancer. 2003 Aug;39(12):1794-806
pubmed: 12888376
Am J Pathol. 1998 Sep;153(3):865-73
pubmed: 9736035
Lancet. 1996 May 18;347(9012):1377-81
pubmed: 8637346
Nature. 2011 Apr 7;472(7341):90-4
pubmed: 21399628
Cancer Biol Ther. 2007 Mar;6(3):383-90
pubmed: 17312385
Cancer Res. 1974 May;34(5):997-1004
pubmed: 4841969
J Theor Biol. 2010 Mar 7;263(1):30-44
pubmed: 19917298
Nat Med. 2009 May;15(5):559-65
pubmed: 19363497
Am J Pathol. 2010 Sep;177(3):1053-64
pubmed: 20651229
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
J Theor Biol. 2006 Jun 21;240(4):521-30
pubmed: 16343545
J Theor Biol. 1976 Feb;56(2):417-34
pubmed: 1271828
Nature. 2016 Dec 22;540(7634):588-592
pubmed: 27974798

Auteurs

Ewa Szczurek (E)

Faculty of Mathematics, Informatics and Mechanics, University of Warsaw, Warsaw, Poland.

Tyll Krüger (T)

Faculty of Electronics, Wrocław University of Science and Technology, Wrocław, Poland.

Barbara Klink (B)

Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
National Center of Genetics, Laboratoir national de santé, Dudelange, Luxembourg.

Niko Beerenwinkel (N)

Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
SIB Swiss Institute of Bioinformatics, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH